Identifying New Regulators of Evolutionarily Conserved Differential Chromosome X Dosage Compensation

Mengbiao Guo,Zhengwen Fang,Bohong Chen,Zhou Songyang,Yuanyan Xiong
DOI: https://doi.org/10.2139/ssrn.4178545
2022-01-01
SSRN Electronic Journal
Abstract:The active X chromosome in mammals is upregulated to balance its dosage to autosomes during evolution. However, it is elusive why the currently known dosage compensation machinery showed uneven and small influence on X genes, necessitating systemic investigation of X dosage in different angles and identification of new dosage regulators. Here, based on >20,000 transcriptomes, we identified two gene groups (ploidy-sensitive chrX [PSX] and ploidy-insensitive chrX [PIX] genes) on chromosome X, with distinct sensitivity to genome ploidy and showing distinct but evolutionarily-conserved (across tissues in both primates and mouse) dosage compensations (X-over-Autosome dosage Ratio, or XAR). We also demonstrated that the trends of XAR-PIX and XAR-PSX in cancers were divergent, with XAR-PIX down-regulated and XAR-PSX up-regulated, compared to corresponding normal tissues, which was supported at both the RNA and protein level across tissue types. We further explored potential XAR regulators systematically and identified and experimentally validated two new independent regulators, mild TP53 (verified in human) and potent ATRX (verified in both human and mouse), expanding the current dosage compensation machinery with only the MOF complex in mammals. Lastly, we presented interesting findings of XAR-PIX and XAR-PSX dynamics during stem cell differentiation and embryo preimplantation, as well as in female-predominant lupus patients. For example, we showed the opposite trends of XARs during stem cell differentiation and in cancer. Collectively, we provided insights to further unravel the mystery of X dosage compensation during evolution.
What problem does this paper attempt to address?